16:25:53 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-15 X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-21 Extra Bolagsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-09-28 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-12 X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-11 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 Kvartalsrapport 2022-Q1
2022-05-11 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-23 Extra Bolagsstämma 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-12 X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-08-11 Extra Bolagsstämma 2020
2020-05-15 X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 Kvartalsrapport 2020-Q1
2020-05-14 Årsstämma 2020
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-08-16 Extra Bolagsstämma 2019
2019-05-17 X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-24 X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-23 Kvartalsrapport 2018-Q1
2018-02-26 Bokslutskommuniké 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-26 X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Idag innehas verksamhet främst inom den nordiska marknaden. Bolaget grundades under 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.
2023-09-04 16:03:00

Acarix, a leader in acoustic and AI-based cardiac diagnostics, partners with Maeva Health, led by Dr. Peter Svalander, CEO, to launch the CADScor System in Mauritius and further on the expansive East African market with a population exceeding 485 million. As a result of the partnership, Maeva has placed an initial order of several Acarix CADScor Systems for rapid diagnosis of cardiac patients directly at the point of care.

Eastern Africa, including nations in the Indian Ocean, incorporates regions with momentous health challenges. Mauritius has adopted a Health Sector Strategic Plan to reduce preventable and premature morbidity, mortality, and disability by addressing their risk factors, with extra focus on cardiovascular disease. Maeva Health provides access to a complete value chain of integrated health diagnostics for advanced health profiling in these key areas with the goal of improving health and quality of life.

"Our patients seek us out for tailored health assessments and guidance to enhance their well-being and optimize their quality of life," commented Dr. Peter Svalander, CEO of Maeva Health. "Considering the high prevalence of cardiovascular disease in Mauritius, the integration of this pioneering Scandinavian technology into our toolbox empowers us to rule out significant coronary artery concerns efficiently and precisely during the initial diagnostic phase, aligning perfectly with Maeva Health's objectives."

"Our main focus is the US market, but we also understand the needs of diverse global markets and patient demographics that can benefit from the CADScor System," commented Helen Ljungdahl Round, Acarix's President and CEO. "One of our strategic initiatives is to provide access to the CADScor System for various patient populations and healthcare systems to ensure equitable healthcare for those who require it. Through our partnership with Maeva Health, we're leveraging the CADScor System's innovation to address early cardiovascular disease assessment among populations in developing countries.”

About AVA and Maeva Health

AVA is an integrated group of companies specializing in medical devices, the health services sector, and several other activities. The group is based in Mauritius and currently employs over 700 people. For more information, please visit www.avagroup.mu

Maeva Health, member of AVA, offers men and women preventive health examinations with a focus on cardiovascular diseases, cancer and diabetes which are the most common causes of premature death in the world. Early detection is key to reducing suffering and excessive medical expenses. For more information, please visit www.maevahealth.mu